Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma

Open access
Corren, Jonathan, Castro, Mario, O'Riordan, Thomas, Hanania, Nicola A., Pavord, Ian D., Quirce, Santiago, Chipps, Bradley E., Wenzel, Sally E., Thangavelu, Karthinathan, Rice, Megan S., Harel, Sivan, Jagerschmidt, Alexandre, Khan, Asif H., Kamat, Siddhesh, Maroni, Jaman, Rowe, Paul, Lu, Yufang, Amin, Nikhil, Pirozzi, Gianluca, Ruddy, Marcella, Graham, Neil M.H., Teper, Ariel·2020·The Journal of Allergy and Clinical Immunology: In Practice

Abstract

Background Dupilumab blocks the shared receptor component for IL-4 and IL-13, key drivers of type 2 inflammation, including IgE-mediated allergic inflammation in asthma. In the LIBERTY ASTHMA QUEST (NCT02414854) study, dupilumab reduced severe asthma exacerbations and improved forced expiratory volume in 1 second (FEV 1 ) in patients with uncontrolled, moderate-to-severe asthma with greater efficacy observed in patients with elevated type 2 inflammatory biomarkers (blood eosinophils and fractional exhaled nitric oxide) at baseline. Objective We assessed dupilumab's effect on key asthma outcomes in QUEST patients with/without evidence of allergic asthma (total serum IgE ≥30 IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35 kU/L at baseline). Methods Severe exacerbation rates and change from baseline in FEV 1 , asthma control, and markers of type 2 inflammation during the 52-week treatment period were assessed. Results In the allergic asthma subgroup (n = 1083), dupilumab 200/300 mg every 2 weeks versus placebo reduced severe asthma exacerbation rates (−36.9%/−45.5%; both P < .01), improved FEV 1 at week 12 (0.13 L/0.16 L; both P < .001; improvements were evident by the first evaluation at week 2) with greater efficacy observed in patients with elevated type 2 inflammatory biomarkers at baseline, and improved asthma control. Dupilumab treatment also resulted in rapid and sustained reductions in type 2 inflammatory biomarkers. Comparable results were observed in patients without evidence of allergic asthma (n = 819). Conclusion Dupilumab reduced severe exacerbation rates, improved FEV 1 and asthma control, and suppressed type 2 inflammatory biomarkers in patients with uncontrolled, moderate-to-severe asthma with or without evidence of allergic asthma, highlighting the key role of IL-4 and IL-13 in airway inflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaip.2019.08.050

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 203

Metadata

Authors
Corren, J., Castro, M., O'Riordan, T., Hanania, N. A., Pavord, I. D., Quirce, S., Chipps, B. E., Wenzel, S. E., Thangavelu, K., Rice, M. S., Harel, S., Jagerschmidt, A., Khan, A. H., Kamat, S., Maroni, J., Rowe, P., Lu, Y., Amin, N., Pirozzi, G., Ruddy, M., Graham, N. M. H., & Teper, A.
Venue
The Journal of Allergy and Clinical Immunology: In Practice
Publisher
Elsevier BV
Published
2020-02
Volume
8
Issue
2
Pages
516-526
ISSN
2213-2198 (ISSN-L)
OpenAlex
W2972864777
Cited by
203
References
4
FWCI
15.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. https://app.cochat.ai/papers/10.1016/j.jaip.2019.08.050
The paper
Corren, J., Castro, M., O'Riordan, T., Hanania, N. A., Pavord, I. D., Quirce, S., Chipps, B. E., Wenzel, S. E., Thangavelu, K., Rice, M. S., Harel, S., Jagerschmidt, A., Khan, A. H., Kamat, S., Maroni, J., Rowe, P., Lu, Y., Amin, N., Pirozzi, G., . . . Teper, A. (2020). Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2019.08.050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.